GAPDH and diffuse large B-cell lymphoma: More recently, a very comprehensive study identified the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a biomarker for distinguishing between OxPhos-DLBCL (GAPDHlow) and non-OxPhos-DLBCL (GAPDHhigh) and a clinical marker for predicting overall survival in patients treated with R-CHOP [418].